Erlotinib and other medicines data
Request for information dated 4 February 2019 on erlotinib, obinutuzumab, pertuzumab, pirfenidone, rutixmab, trastuzumab, melanoma, multiple sclerosis and gefitinib.
01 April 2019
[Name and contact details redacted]
Dear [Name redacted]
REQUEST FOR INFORMATION
I refer to your request dated 04 February 2019 under the Official Information Act (OIA) and my letter to you dated 05 March 2019, which notified you of an extension of the time to make a decision on your request.
You requested information on erlotinib, obinutuzumab, pertuzumab, pirfenidone, rituximab, trastuzumab, melanoma, multiple sclerosis and gefitinib.
The information you have requested is attached to this letter, subject to the provisions stated below.
Where the request for information is at DHB level, PHARMAC does not hold this information and therefore this part of your request is refused under section 18(g) of the OIA as the information is not held by PHARMAC, and we have no reason to believe it is held by another agency in that form.
Please note that PHARMAC does not hold any data on prescriptions which did not result in a dispensing. A prescription (or script) is counted as having no repeats (stat dispensing) or is the first repeat of a number of dispensings. It is important to note that PHARMAC does not hold any data on prescriptions which did not result in a dispensing. The information has been provided per calendar year.
The following requests for information would require PHARMAC to create new information, which is not classified as official information under the OIA and in this respect this part of your request is refused under section 18(g) of the OIA as the information is not held by PHARMAC, and we have no reason to believe it is held by another agency in that form.
- Pirfenidone: Questions 7 and 8
- Rituximab: Question 6
- Multiple Sclerosis: Questions 3 and 5
In respect of rituximab: Question 7, PHARMAC does not hold this information at this time but will provide it without undue delay and therefore this part of your request is refused at this time under section 18(g) of the OIA as the information is not held by PHARMAC, and we have no reason to believe it is held by another agency in that form.
Please note you have the right, by way of complaint under section 28(3) of the OIA to an Ombudsman, to seek an investigation and review of our decision
We trust that the provision of this information answers your queries, if you have any further questions please feel free to contact us again.
Yours sincerely
[Alison Hill's signature]
Alison Hill
Director, Engagement and Implementation
Official Information Request data: [Name redacted]
Erlonitinib
- How many unique patients received erlotinib in total in the following years? 2016, 2017, 2018
Calendar year |
Number of patients |
---|---|
2016 |
149 |
2017 |
166 |
2018 |
175 |
2. How many patients, dispensings and prescriptions of erlotinib were there in each month of the following years? 2016, 2017, 2018
Month |
Number of patients |
Number of dispensings |
Number of scripts |
---|---|---|---|
1/01/2016 |
61 |
76 |
34 |
1/02/2016 |
60 |
72 |
36 |
1/03/2016 |
62 |
75 |
29 |
1/04/2016 |
57 |
67 |
33 |
1/05/2016 |
64 |
81 |
41 |
1/06/2016 |
62 |
69 |
37 |
1/07/2016 |
60 |
71 |
33 |
1/08/2016 |
63 |
71 |
41 |
1/09/2016 |
58 |
64 |
28 |
1/10/2016 |
63 |
70 |
35 |
1/11/2016 |
64 |
82 |
50 |
1/12/2016 |
65 |
81 |
35 |
1/01/2017 |
59 |
69 |
36 |
1/02/2017 |
69 |
83 |
49 |
1/03/2017 |
75 |
92 |
42 |
1/04/2017 |
72 |
88 |
48 |
1/05/2017 |
76 |
92 |
50 |
1/06/2017 |
65 |
77 |
30 |
1/07/2017 |
84 |
108 |
63 |
1/08/2017 |
79 |
93 |
50 |
1/09/2017 |
74 |
89 |
52 |
1/10/2017 |
82 |
102 |
43 |
1/11/2017 |
81 |
90 |
47 |
1/12/2017 |
78 |
96 |
38 |
1/01/2018 |
67 |
84 |
40 |
1/02/2018 |
69 |
81 |
33 |
1/03/2018 |
69 |
81 |
46 |
1/04/2018 |
71 |
84 |
44 |
1/05/2018 |
83 |
99 |
46 |
1/06/2018 |
70 |
79 |
38 |
1/07/2018 |
80 |
97 |
50 |
1/08/2018 |
81 |
98 |
46 |
1/09/2018 |
78 |
87 |
38 |
1/10/2018 |
83 |
101 |
55 |
1/11/2018 |
96 |
114 |
59 |
1/12/2018 |
87 |
108 |
53 |
3. How many new patients (patients starting treatment) received erlotinib in each month of the following years? 2016, 2017, 2018
Month |
Number of new patients |
---|---|
1/01/2016 |
6 |
1/02/2016 |
5 |
1/03/2016 |
8 |
1/04/2016 |
4 |
1/05/2016 |
8 |
1/06/2016 |
9 |
1/07/2016 |
5 |
1/08/2016 |
6 |
1/09/2016 |
6 |
1/10/2016 |
7 |
1/11/2016 |
10 |
1/12/2016 |
8 |
1/01/2017 |
3 |
1/02/2017 |
15 |
1/03/2017 |
8 |
1/04/2017 |
6 |
1/05/2017 |
6 |
1/06/2017 |
5 |
1/07/2017 |
10 |
1/08/2017 |
7 |
1/09/2017 |
6 |
1/10/2017 |
8 |
1/11/2017 |
11 |
1/12/2017 |
3 |
1/01/2018 |
6 |
1/02/2018 |
3 |
1/03/2018 |
14 |
1/04/2018 |
7 |
1/05/2018 |
11 |
1/06/2018 |
7 |
1/07/2018 |
7 |
1/08/2018 |
10 |
1/09/2018 |
6 |
1/10/2018 |
5 |
1/11/2018 |
12 |
1/12/2018 |
10 |
Obinutuzumab
- How many new patients (patients starting treatment) received treatment with obinutuzumab reported by individual month (month of first dispensing) for 2018?
Month |
Number of patients |
---|---|
1/01/2018 |
5 |
1/02/2018 |
6 |
1/03/2018 |
6 |
1/04/2018 |
3 |
1/05/2018 |
11 |
1/06/2018 |
2 |
1/07/2018 |
1 |
1/08/2018 |
5 |
1/09/2018 |
3 |
1/10/2018 |
6 |
1/11/2018 |
1 |
1/12/2018 |
2 |
- How many patients have had more than 1 dispensing of obinutuzumab reported by individual month for 2018?
Month |
Number of patients |
---|---|
1/01/2018 |
7 |
1/02/2018 |
8 |
1/03/2018 |
11 |
1/04/2018 |
6 |
1/05/2018 |
15 |
1/06/2018 |
6 |
1/07/2018 |
7 |
1/08/2018 |
6 |
1/09/2018 |
4 |
1/10/2018 |
9 |
1/11/2018 |
5 |
1/12/2018 |
3 |
Pertuzumab
- How many new patients (patients starting treatment) were approved for mBC treatment with Pertuzumab under Special Authority in 2018? Reported by DHB of dispensing and individual month (month of first dispensing).
Month |
Number of patients |
---|---|
1/01/2018 |
3 |
1/02/2018 |
4 |
1/03/2018 |
4 |
1/04/2018 |
4 |
1/05/2018 |
10 |
1/06/2018 |
7 |
1/07/2018 |
9 |
1/08/2018 |
11 |
1/09/2018 |
12 |
1/10/2018 |
8 |
1/11/2018 |
8 |
1/12/2018 |
6 |
Pirfenidone
- In total, how many different patients received pirfenidone across 2017 and 2018 combined?
230
- How many patients received pirfenidone in the following years? 2017, 2018
Calendar year |
Number of patients |
---|---|
2017 |
132 |
2018 |
165 |
- How many new patients started treatment each month in 2017 and 2018?
Month |
Number of new patients |
---|---|
1/01/2017 |
19 |
1/02/2017 |
19 |
1/03/2017 |
16 |
1/04/2017 |
11 |
1/05/2017 |
11 |
1/06/2017 |
10 |
1/07/2017 |
11 |
1/08/2017 |
7 |
1/09/2017 |
2 |
1/10/2017 |
8 |
1/11/2017 |
12 |
1/12/2017 |
6 |
1/01/2018 |
7 |
1/02/2018 |
12 |
1/03/2018 |
9 |
1/04/2018 |
8 |
1/05/2018 |
11 |
1/06/2018 |
3 |
1/07/2018 |
11 |
1/08/2018 |
7 |
1/09/2018 |
9 |
1/10/2018 |
6 |
1/11/2018 |
8 |
1/12/2018 |
7 |
- On average, how many units was each patient dispensed at initiation?
Calendar year |
Number of units |
---|---|
2017 |
272 |
2018 |
267 |
- On average, how many units was each patient dispensed in repeat dispensing?
Calendar year |
Number of units |
---|---|
2017 |
256 |
2018 |
255 |
- How many repeat dispensings were there each month in 2017 and 2018 (not first dispensings)
Month |
Number of dispensings |
---|---|
1/01/2017 |
2 |
1/02/2017 |
16 |
1/03/2017 |
39 |
1/04/2017 |
42 |
1/05/2017 |
63 |
1/06/2017 |
57 |
1/07/2017 |
52 |
1/08/2017 |
70 |
1/09/2017 |
60 |
1/10/2017 |
58 |
1/11/2017 |
62 |
1/12/2017 |
63 |
1/01/2018 |
60 |
1/02/2018 |
45 |
1/03/2018 |
61 |
1/04/2018 |
70 |
1/05/2018 |
70 |
1/06/2018 |
83 |
1/07/2018 |
79 |
1/08/2018 |
84 |
1/09/2018 |
78 |
1/10/2018 |
92 |
1/11/2018 |
79 |
1/12/2018 |
83 |
- How many patients stopped treatment in 2017 and 2018 (i.e. did not have a repeat dispensing)? Stopping treatment is defined as having received no dispensings for a minimum of 3 months.
Please refer to PHARMAC’s response in the covering letter.
- On average, how many units (tablets) were those patients dispensed before they stopped treatment?
Please refer to PHARMAC’s response in the covering letter.
- How many patients have received only 1 dispensing of pirfenidone in each month of 2017 and 2018?
Month |
Number of patients |
---|---|
1/01/2017 |
18 |
1/02/2017 |
29 |
1/03/2017 |
40 |
1/04/2017 |
41 |
1/05/2017 |
53 |
1/06/2017 |
51 |
1/07/2017 |
44 |
1/08/2017 |
59 |
1/09/2017 |
52 |
1/10/2017 |
46 |
1/11/2017 |
54 |
1/12/2017 |
52 |
1/01/2018 |
47 |
1/02/2018 |
51 |
1/03/2018 |
52 |
1/04/2018 |
59 |
1/05/2018 |
59 |
1/06/2018 |
62 |
1/07/2018 |
59 |
1/08/2018 |
58 |
1/09/2018 |
65 |
1/10/2018 |
65 |
1/11/2018 |
62 |
1/12/2018 |
63 |
10. How many pirfenidone scripts, dispensings, and units (tablets) were there in each month of 2017 and 2018?
Month |
Number of units dispensed |
Number of dispensings |
Number of scripts |
---|---|---|---|
1/01/2017 |
5940 |
21 |
19 |
1/02/2017 |
9450 |
35 |
20 |
1/03/2017 |
14850 |
55 |
20 |
1/04/2017 |
11928 |
53 |
23 |
1/05/2017 |
19188 |
74 |
37 |
1/06/2017 |
18072 |
67 |
24 |
1/07/2017 |
15318 |
63 |
26 |
1/08/2017 |
20331 |
77 |
34 |
1/09/2017 |
16074 |
62 |
25 |
1/10/2017 |
16208 |
66 |
25 |
1/11/2017 |
19209 |
74 |
32 |
1/12/2017 |
17469 |
69 |
30 |
1/01/2018 |
17499 |
67 |
27 |
1/02/2018 |
13797 |
57 |
26 |
1/03/2018 |
19071 |
70 |
31 |
1/04/2018 |
19835 |
78 |
37 |
1/05/2018 |
20219 |
81 |
32 |
1/06/2018 |
21369 |
86 |
33 |
1/07/2018 |
22354 |
90 |
44 |
1/08/2018 |
22657 |
91 |
30 |
1/09/2018 |
23496 |
87 |
33 |
1/10/2018 |
25674 |
98 |
42 |
1/11/2018 |
21574 |
87 |
37 |
1/12/2018 |
21229 |
90 |
33 |
Rituximab
- How many initial Post-transplant applications were approved under Special Authority in 2018?
21
- How many initial Indolent, low-grade lymphomas applications were approved under Special Authority in 2018?
337
- How many Special Authority applications were approved for indolent low grade NHL with relapsed disease following prior chemotherapy?
139
- How many Special Authority applications were approved for low grade lymphoma requiring first-line systemic chemotherapy?
198
- How many initial Aggressive CD20 positive NHL applications were approved under Special Authority?
413
- How many Special Authority applications were approved for naïve aggressive CD20 positive NHL?
394
- How many Special Authority applications were approved for aggressive CD20 positive NHL with relapsed disease following prior chemotherapy?
19
- How many initial Special Authority Chronic Lymphocytic Leukaemia applications were approved under Special Authority?
80
- How many were approved where the patient is chemotherapy treatment naïve?
73
- b. How many were approved where the patient's disease has relapsed?
7
- How many renewals were there for:
- Post-transplant applications approved in 2018.
0
- Indolent, low grade lymphomas applications approved in 2018.
48
- Aggressive CD20 positive NHL applications approved in 2018.
16
- Chronic Lymphocytic Leukaemia applications approved in 2018.
0
- How many patients approved for Chronic Lymphocytic Leukaemia under Special Authority for bendamustine (Special Authority 1667) were receiving treatment in combination with rituximab in 2018?
Please refer to PHARMAC’s response in the covering letter.
- How many vials of rituximab were dispensed through the HML reported by DHB, formulation (100mg vials and 500mg vials), and month.
Please refer to PHARMAC’s response in the covering letter.
- How many Special Authority applications were there for initial treatment of Rheumatoid arthritis in 2018?
0
- How many of Special Authority applications were there for the re treatment of Rheumatoid arthritis in 2018?
0
Trastuzumab
Note: We have defined ‘new patients’ as ‘initial approvals’.
Month |
1. How many new patients were approved for mBC treatment under Special Authority in 2018 reported by DHB of dispensing and individual month where trastuzumab will not be given in combination with pertzumab? |
2. How many new patients were approved for mBC treatment under Special Authority in 2018 reported by DHB of dispensing and individual month where trastuzumab is to be administered in combination with pertzumab? |
3. How many renewals were approved for mBC treatment under Special Authority in 2018? Reported by DHB of dispensing and individual month. |
4. How many new patients were approved for eBC treatment under Special Authority in 2018, reported by DHB of dispensing and individual month. |
---|---|---|---|---|
1/01/2018 |
1 |
4 |
18 |
30 |
1/02/2018 |
0 |
4 |
11 |
32 |
1/03/2018 |
1 |
4 |
6 |
32 |
1/04/2018 |
0 |
2 |
17 |
40 |
1/05/2018 |
1 |
8 |
20 |
32 |
1/06/2018 |
1 |
4 |
13 |
28 |
1/07/2018 |
2 |
10 |
9 |
33 |
1/08/2018 |
2 |
8 |
13 |
28 |
1/09/2018 |
2 |
11 |
4 |
44 |
1/10/2018 |
0 |
7 |
15 |
25 |
1/11/2018 |
4 |
6 |
13 |
33 |
1/12/2018 |
1 |
6 |
6 |
30 |
5. How many Special Authority approvals were there for ebc? Reported by DHB of dispensing and individual month in 2018, for each of the following Special Authority criteria?
Month |
a. 9 weeks concurrent treatment with adjuvant chemotherapy is planned |
b. 12 months concurrent treatment with adjuvant chemotherapy is planned |
c. 12 months sequential treatment following adjuvant chemotherapy is planned |
d. 12 months treatment with neoadjuvant and adjuvant chemotherapy is planned |
e. Other treatment regimen, in association with adjuvant chemotherapy, is planned |
---|---|---|---|---|---|
1/01/2018 |
0 |
21 |
3 |
4 |
2 |
1/02/2018 |
1 |
27 |
2 |
1 |
1 |
1/03/2018 |
1 |
27 |
1 |
5 |
2 |
1/04/2018 |
1 |
26 |
3 |
8 |
2 |
1/05/2018 |
1 |
26 |
2 |
2 |
1 |
1/06/2018 |
0 |
18 |
1 |
4 |
6 |
1/07/2018 |
1 |
23 |
4 |
5 |
0 |
1/08/2018 |
1 |
19 |
2 |
5 |
1 |
1/09/2018 |
1 |
31 |
2 |
8 |
2 |
1/10/2018 |
0 |
15 |
4 |
3 |
3 |
1/11/2018 |
0 |
18 |
7 |
7 |
2 |
1/12/2018 |
1 |
23 |
2 |
4 |
0 |
Month |
6. How many eBC renewals were approved for treatment under Special Authority in 2018 reported by DHB of dispensing and individual month where trastuzumab will not be given in combination with pertuzumab? |
7. How many eBC renewals were approved for treatment under Special Authority in 2018 reported by DHB of dispensing and individual month where trastuzumab is to be administered in combination with pertuzumab? |
---|---|---|
1/01/2018 |
0 |
0 |
1/02/2018 |
0 |
0 |
1/03/2018 |
0 |
0 |
1/04/2018 |
0 |
0 |
1/05/2018 |
0 |
2 |
1/06/2018 |
0 |
1 |
1/07/2018 |
0 |
0 |
1/08/2018 |
0 |
1 |
1/09/2018 |
0 |
0 |
1/10/2018 |
0 |
0 |
1/11/2018 |
0 |
0 |
1/12/2018 |
0 |
1 |
Melanoma
Note: We have defined ‘new patients’ as ‘initial approvals’.
- How many unique patients have been approved under Special Authority forms 1656 and 1657 the following years? 2016, 2017, 2018
From further discussion with requestor:
a. The total number of SA approvals for Nivolumab and Pembrolizumab for those years (all SA forms applicable).
Calendar Year |
Nivolumab (ALL SA) |
Pembrolizumab (ALL SA) |
---|---|---|
2016 |
84 |
191 |
2017 |
63 |
608 |
2018 |
53 |
709 |
b. The total number of SA approvals specifically for SA1656 and SA1657.
Calendar Year |
Nivolumab (SA1656) |
Pembrolizumab (SA1657) |
---|---|---|
2016 |
0 |
0 |
2017 |
29 |
311 |
2018 |
53 |
709 |
c. The total unique patients who received a dispensing of Nivolumab and Pembrolizumab for those years (all SA forms applicable).
Chemical name |
Calendar year |
Total patients |
---|---|---|
Nivolumab |
2016 |
52 |
Nivolumab |
2017 |
33 |
Nivolumab |
2018 |
29 |
Pembrolizumab |
2016 |
166 |
Pembrolizumab |
2017 |
386 |
Pembrolizumab |
2018 |
442 |
- How many patients, dispensings, and prescriptions were there under Special Authority forms 1656 and 1657 in each month of the following years? 2016, 2017, 2018
Note: data provided for question 2 is for all Special Authority forms related to Nivolumab and Pembrolizumab.
Chemical name |
Month |
Number of patients |
Number of dispensings |
Number of scripts |
---|---|---|---|---|
Nivolumab |
1/07/2016 |
31 |
74 |
74 |
1/08/2016 |
44 |
122 |
122 |
|
1/09/2016 |
45 |
126 |
126 |
|
1/10/2016 |
34 |
85 |
85 |
|
1/11/2016 |
28 |
72 |
72 |
|
1/12/2016 |
27 |
77 |
77 |
|
1/01/2017 |
25 |
65 |
65 |
|
1/02/2017 |
28 |
73 |
73 |
|
1/03/2017 |
26 |
71 |
71 |
|
1/04/2017 |
24 |
55 |
55 |
|
1/05/2017 |
27 |
70 |
70 |
|
1/06/2017 |
25 |
70 |
70 |
|
1/07/2017 |
25 |
65 |
65 |
|
1/08/2017 |
24 |
70 |
70 |
|
1/09/2017 |
20 |
50 |
50 |
|
1/10/2017 |
22 |
55 |
55 |
|
1/11/2017 |
20 |
55 |
55 |
|
1/12/2017 |
24 |
68 |
68 |
|
1/01/2018 |
23 |
58 |
58 |
|
1/02/2018 |
22 |
54 |
54 |
|
1/03/2018 |
24 |
66 |
66 |
|
1/04/2018 |
23 |
56 |
56 |
|
1/05/2018 |
23 |
62 |
62 |
|
1/06/2018 |
21 |
52 |
52 |
|
1/07/2018 |
20 |
50 |
50 |
|
1/08/2018 |
18 |
47 |
47 |
|
1/09/2018 |
18 |
43 |
43 |
|
1/10/2018 |
15 |
39 |
39 |
|
1/11/2018 |
15 |
42 |
42 |
|
1/12/2018 |
15 |
38 |
38 |
|
Pembrolizumab |
1/07/2016 |
77 |
97 |
97 |
1/08/2016 |
98 |
119 |
119 |
|
1/09/2016 |
117 |
168 |
168 |
|
1/10/2016 |
130 |
170 |
170 |
|
1/11/2016 |
140 |
192 |
192 |
|
1/12/2016 |
141 |
191 |
191 |
|
1/01/2017 |
163 |
251 |
251 |
|
1/02/2017 |
159 |
218 |
218 |
|
1/03/2017 |
156 |
223 |
223 |
|
1/04/2017 |
169 |
255 |
255 |
|
1/05/2017 |
165 |
220 |
220 |
|
1/06/2017 |
165 |
245 |
245 |
|
1/07/2017 |
169 |
235 |
235 |
|
1/08/2017 |
177 |
253 |
253 |
|
1/09/2017 |
187 |
278 |
278 |
|
1/10/2017 |
177 |
237 |
237 |
|
1/11/2017 |
194 |
287 |
287 |
|
1/12/2017 |
195 |
260 |
260 |
|
1/01/2018 |
202 |
296 |
296 |
|
1/02/2018 |
201 |
273 |
273 |
|
1/03/2018 |
214 |
319 |
319 |
|
1/04/2018 |
209 |
290 |
290 |
|
1/05/2018 |
213 |
304 |
304 |
|
1/06/2018 |
235 |
368 |
368 |
|
1/07/2018 |
251 |
337 |
337 |
|
1/08/2018 |
252 |
368 |
368 |
|
1/09/2018 |
254 |
367 |
367 |
|
1/10/2018 |
245 |
339 |
339 |
|
1/11/2018 |
77 |
97 |
97 |
|
1/12/2018 |
98 |
119 |
119 |
- How many new patients (patients starting treatment) were there under Special Authority forms 1656 and 1657 in each month of the following years? 2016, 2017, 2018
Note: data provided for question 3 is for all Special Authority forms related to Nivolumab and Pembrolizumab.
Month |
Nivolumab |
Pembrolizumab |
---|---|---|
1/07/2016 |
30 |
76 |
1/08/2016 |
16 |
31 |
1/09/2016 |
4 |
24 |
1/10/2016 |
1 |
35 |
1/11/2016 |
1 |
22 |
1/12/2016 |
0 |
20 |
1/01/2017 |
0 |
33 |
1/02/2017 |
3 |
26 |
1/03/2017 |
0 |
15 |
1/04/2017 |
0 |
21 |
1/05/2017 |
1 |
17 |
1/06/2017 |
0 |
20 |
1/07/2017 |
1 |
22 |
1/08/2017 |
1 |
25 |
1/09/2017 |
1 |
25 |
1/10/2017 |
0 |
18 |
1/11/2017 |
0 |
25 |
1/12/2017 |
1 |
17 |
1/01/2018 |
0 |
22 |
1/02/2018 |
0 |
18 |
1/03/2018 |
1 |
23 |
1/04/2018 |
1 |
17 |
1/05/2018 |
1 |
24 |
1/06/2018 |
1 |
25 |
1/07/2018 |
0 |
29 |
1/08/2018 |
0 |
25 |
1/09/2018 |
1 |
25 |
1/10/2018 |
0 |
15 |
1/11/2018 |
1 |
76 |
1/12/2018 |
0 |
31 |
Multiple Sclerosis
Note: We have defined ‘new patients’ as ‘initial approvals’.
- How many patients have been approved under Special Authority forms 1559, 1560, 1562, 1563, 1564 for MS treatment? In 2016, 2017, 2018
Calendar year |
Number of patients |
---|---|
2016 |
878 |
2017 |
1144 |
2018 |
1323 |
- How many new patients have been approved under Special Authority forms 1559, 1560, 1562, 1563, 1564 each month from 2016-2018?
Month |
Number of patients |
---|---|
1/01/2016 |
0 |
1/02/2016 |
81 |
1/03/2016 |
78 |
1/04/2016 |
78 |
1/05/2016 |
76 |
1/06/2016 |
115 |
1/07/2016 |
52 |
1/08/2016 |
113 |
1/09/2016 |
58 |
1/10/2016 |
61 |
1/11/2016 |
102 |
1/12/2016 |
64 |
1/01/2017 |
50 |
1/02/2017 |
112 |
1/03/2017 |
69 |
1/04/2017 |
94 |
1/05/2017 |
130 |
1/06/2017 |
67 |
1/07/2017 |
90 |
1/08/2017 |
125 |
1/09/2017 |
135 |
1/10/2017 |
87 |
1/11/2017 |
84 |
1/12/2017 |
101 |
1/01/2018 |
77 |
1/02/2018 |
117 |
1/03/2018 |
117 |
1/04/2018 |
109 |
1/05/2018 |
130 |
1/06/2018 |
97 |
1/07/2018 |
86 |
1/08/2018 |
162 |
1/09/2018 |
101 |
1/10/2018 |
104 |
1/11/2018 |
107 |
1/12/2018 |
116 |
- How many patients approved under Special Authority forms 1559, 1560, 1562, 1563, 1564 have switched treatment to a new MS treatment once, twice, or three or more times?
Please refer to PHARMAC’s response in the covering letter.
5. For patients who have switched treatment once, on average how long are they on their first MS treatment?
Please refer to PHARMAC’s response in the covering letter.
Gefitinib
- How many unique patients received gefitinib in total in the following years? 2016, 2017, 2018
Calendar year |
Total unique patients |
---|---|
2016 |
94 |
2017 |
97 |
2018 |
98 |
2. How many patients, dispensing and prescriptions of gefitinib were there in each month of the following years? 2016, 2017, 2018
Month |
Number of patients |
Number units dispensed |
Number of dispensings |
Number of scripts |
---|---|---|---|---|
1/01/2016 |
47 |
1831 |
61 |
19 |
1/02/2016 |
40 |
1441 |
48 |
23 |
1/03/2016 |
41 |
1429 |
45 |
19 |
1/04/2016 |
41 |
1616 |
50 |
18 |
1/05/2016 |
42 |
1550 |
50 |
25 |
1/06/2016 |
40 |
1496 |
49 |
24 |
1/07/2016 |
37 |
1466 |
45 |
17 |
1/08/2016 |
44 |
1764 |
49 |
25 |
1/09/2016 |
41 |
1610 |
48 |
22 |
1/10/2016 |
47 |
1599 |
51 |
18 |
1/11/2016 |
46 |
1584 |
51 |
26 |
1/12/2016 |
48 |
1706 |
52 |
22 |
1/01/2017 |
41 |
1376 |
46 |
13 |
1/02/2017 |
43 |
1612 |
50 |
27 |
1/03/2017 |
46 |
1672 |
53 |
23 |
1/04/2017 |
48 |
1651 |
53 |
25 |
1/05/2017 |
49 |
1886 |
60 |
26 |
1/06/2017 |
44 |
1554 |
52 |
20 |
1/07/2017 |
44 |
1586 |
50 |
21 |
1/08/2017 |
50 |
1978 |
62 |
29 |
1/09/2017 |
48 |
1595 |
52 |
24 |
1/10/2017 |
47 |
1753 |
55 |
19 |
1/11/2017 |
47 |
1800 |
54 |
23 |
1/12/2017 |
46 |
1590 |
50 |
24 |
1/01/2018 |
46 |
1590 |
51 |
22 |
1/02/2018 |
45 |
1650 |
51 |
17 |
1/03/2018 |
52 |
1845 |
60 |
27 |
1/04/2018 |
52 |
1961 |
58 |
25 |
1/05/2018 |
48 |
1768 |
56 |
24 |
1/06/2018 |
45 |
1663 |
50 |
26 |
1/07/2018 |
55 |
2024 |
65 |
30 |
1/08/2018 |
46 |
1740 |
56 |
25 |
1/09/2018 |
43 |
1575 |
48 |
27 |
1/10/2018 |
51 |
1875 |
58 |
25 |
1/11/2018 |
49 |
1950 |
56 |
22 |
1/12/2018 |
43 |
1466 |
47 |
26 |
3. How many new patients (patients starting treatment) received gefitinib in each month of the following years? 2016, 2017, 2018
Month |
Number of new patients |
---|---|
1/01/2016 |
4 |
1/02/2016 |
3 |
1/03/2016 |
3 |
1/04/2016 |
4 |
1/05/2016 |
2 |
1/06/2016 |
1 |
1/07/2016 |
6 |
1/08/2016 |
4 |
1/09/2016 |
4 |
1/10/2016 |
3 |
1/11/2016 |
7 |
1/12/2016 |
5 |
1/01/2017 |
3 |
1/02/2017 |
6 |
1/03/2017 |
7 |
1/04/2017 |
4 |
1/05/2017 |
3 |
1/06/2017 |
2 |
1/07/2017 |
7 |
1/08/2017 |
2 |
1/09/2017 |
5 |
1/10/2017 |
5 |
1/11/2017 |
3 |
1/12/2017 |
4 |
1/01/2018 |
3 |
1/02/2018 |
4 |
1/03/2018 |
3 |
1/04/2018 |
2 |
1/05/2018 |
4 |
1/06/2018 |
4 |
1/07/2018 |
3 |
1/08/2018 |
5 |
1/09/2018 |
4 |
1/10/2018 |
4 |
1/11/2018 |
7 |
1/12/2018 |
4 |